ESR2 and melanoma: Based on our results as well as on these recently reported observations, we hypothesize that ERβ agonists might effectively reduce the proliferation of melanoma cells harboring the NRAS mutation, through the specific inhibition of the activity of one of the two downstream signaling pathways: the PI3K/Akt cascade.